Drug intelligence / Profile preview

2-(diethylamino)ethyl 2-acetyloxybenzoate hydrochloride

Development stage: Phase 2
Lead developer: Jiangsu XinChen-Techfields Pharma
Modality: Small Molecules
Administration: Topical, Cutaneous

Overview

TF0023 is a prodrug of aspirin developed by Techfields Pharma for the treatment of ischemic strokes, COVID-19 infections, myocardial infarction, pulmonary embolism, and chronic heart failure. It is formulated as a topical spray or cutaneous solution and acts as an antithrombotic agent. The primary mechanism of action is thrombin inhibition. Clinical trials have reached Phase II for several indications including COVID-19 and ischemic stroke. Development for type 2 diabetes mellitus has been discontinued[1][2][3][5][7].

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on 2-(diethylamino)ethyl 2-acetyloxybenzoate hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-(diethylamino)ethyl 2-acetyloxybenzoate hydrochloride.

Explore the full profile